美国医疗保健局推出对老年人的CBD补偿试点,引发了安全和监管方面的担忧. CMS launches CBD reimbursement pilot for seniors, sparking safety and regulatory concerns.

美国医疗保险和医疗补助中心正在启动试点计划, 为患有慢性疼痛的老年人提供CBD产品退款. The Centers for Medicare & Medicaid Services is launching a pilot program to reimburse CBD products for seniors with chronic pain, bypassing FDA approval requirements. 批评人士警告说, 不受监管的CBD产品在强度和THC含量上有所不同, 这可能会给安全带来风险并破坏已有的药物标准. Critics warn that unregulated CBD products vary in potency and THC content, posing safety risks and undermining established drug standards. 这一计划与限制THC为0.3%的联邦大麻法相冲突, 并且引发了人们对在没有科学验证的情况下建立"影子医疗系统"的担忧. The plan conflicts with federal hemp laws limiting THC to 0.3% and raises concerns about creating a "shadow medical system" without scientific validation. 虽然CMS称其为数据收集工作, 但反对者表示它有可能使弱势患者接触到无效或有害的治疗方法, 并破坏对联邦医疗监管的信任. While CMS calls it a data-gathering effort, opponents say it risks exposing vulnerable patients to ineffective or harmful treatments and erodes trust in federal healthcare oversight.